Do global clinical trials make the $100-200mn Indian NCE a mirage?
This article was originally published in Scrip
Executive Summary
Indian industry pundits now have very mixed views on whether the $100-200 million once touted as the potential cost to develop and market an Indian new chemical entity (NCE) - just 10-20% of the globally accepted $1 billion figure - is truly feasible. Co-development and licensing options for NCEs are now high on the agenda of most Indian R&D firms as they evolve, more so in the absence of risk capital.